MLN9708
10mM in DMSO
- Product Code: 204599
CAS:
1201902-80-8
| Molecular Weight: | 517.12 g./mol | Molecular Formula: | C₂₀H₂₃BCl₂N₂O₉ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
MLN9708 is a proteasome inhibitor primarily used in the treatment of multiple myeloma, a type of blood cancer. It works by blocking the degradation of proteins involved in cell cycle regulation and apoptosis, leading to the accumulation of damaged proteins in cancer cells and ultimately triggering their death. The compound shows improved pharmacokinetic properties over earlier proteasome inhibitors, allowing for oral administration and more consistent drug exposure. It has been investigated in clinical trials both as a monotherapy and in combination with other anti-myeloma agents such as immunomodulatory drugs and corticosteroids. Its mechanism also shows potential in treating other hematologic malignancies and solid tumors, though research in these areas is ongoing. Due to its targeted action on the proteasome system, MLN9708 offers a strategic approach in cancer therapy with a focus on disrupting protein homeostasis in malignant cells.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿19,490.00 |
+
-
|
MLN9708
MLN9708 is a proteasome inhibitor primarily used in the treatment of multiple myeloma, a type of blood cancer. It works by blocking the degradation of proteins involved in cell cycle regulation and apoptosis, leading to the accumulation of damaged proteins in cancer cells and ultimately triggering their death. The compound shows improved pharmacokinetic properties over earlier proteasome inhibitors, allowing for oral administration and more consistent drug exposure. It has been investigated in clinical trials both as a monotherapy and in combination with other anti-myeloma agents such as immunomodulatory drugs and corticosteroids. Its mechanism also shows potential in treating other hematologic malignancies and solid tumors, though research in these areas is ongoing. Due to its targeted action on the proteasome system, MLN9708 offers a strategic approach in cancer therapy with a focus on disrupting protein homeostasis in malignant cells.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :